Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) today announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV) (the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE